What is the genetic mutation responsible for hemochromatosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Genetic Mutation in Hemochromatosis

The C282Y mutation in the HFE gene on chromosome 6 is the primary genetic mutation responsible for hereditary hemochromatosis, present in more than 90% of affected patients, with most being homozygous (C282Y/C282Y) and inheriting the condition in an autosomal recessive pattern. 1, 2

Primary Mutation: C282Y

  • The C282Y mutation accounts for 85-90% of all hereditary hemochromatosis cases and is found in approximately 0.44-0.5% of individuals of northern European descent as homozygotes 2, 3

  • Most clinically affected patients are homozygous for C282Y (C282Y/C282Y), meaning they inherited the mutation from both parents 1, 2

  • The mutation is transmitted in an autosomal recessive pattern, requiring two copies of the mutated gene for full disease expression 1, 2

Secondary Mutations

  • H63D mutation is the second most common HFE mutation, though its clinical significance is less certain than C282Y 1

  • Compound heterozygotes (C282Y/H63D) account for only 3-5% of hemochromatosis cases and can develop iron overload, though typically less severe 2

  • S65C mutation is much rarer with an allelic frequency of approximately 0.5%, with higher prevalence in certain regions like Brittany, France 2

Non-HFE Mutations (10-15% of Cases)

The remaining 10-15% of hereditary hemochromatosis involves mutations in non-HFE genes 4:

  • HJV gene (chromosome 1q) - most common cause of juvenile hemochromatosis, coding for hemojuvelin 4

  • HAMP gene - codes for hepcidin (the principal iron-regulatory hormone), causes juvenile hemochromatosis but less common than HJV 4

  • TFR2 gene - causes adult-onset hemochromatosis similar to HFE-related disease 4

  • SLC40A1 gene - causes ferroportin disease (type 4 hemochromatosis) with unique autosomal dominant inheritance pattern, unlike the recessive HFE mutations 4

Geographic Distribution

  • The C282Y mutation shows highest frequencies in Ireland (12.5%) and decreases toward Southern Europe (approaching 0%) 2

  • HFE mutations predominate in Northern European ancestry populations, while non-HFE related cases are more common in Mediterranean populations 4

Critical Penetrance Caveat

  • Not all C282Y homozygotes develop clinical disease - fewer than 10% develop full clinical manifestations despite genetic susceptibility 5

  • Variable penetrance means that having the homozygous C282Y mutation does not guarantee symptomatic disease, though all homozygotes show elevated transferrin saturation 2

  • This variable expression makes genetic counseling essential when discussing inheritance patterns with families 2

Clinical Implications for Testing

  • Genetic testing should focus on C282Y and H63D mutations as the primary targets, as these account for the vast majority of cases 1, 4

  • Testing is indicated for first-degree relatives of confirmed cases and patients with unexplained elevated serum ferritin (>200 µg/mL) and transferrin saturation (>55%) 1, 5

  • Early diagnosis before development of cirrhosis or diabetes normalizes survival, making genetic identification clinically critical 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HFE Gene Mutation and Hereditary Hemochromatosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Haemochromatosis.

Nature reviews. Disease primers, 2018

Guideline

Hemochromatosis Gene Panel Composition

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hemochromatosis Management and Pathophysiology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.